Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
This study is currently recruiting participants.
Study NCT00135200 Information provided by University of Michigan Cancer Center
First Received: August 24, 2005 Last Updated: March 7, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Myeloma
Additional conditions recognized in this trial
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
Iodine I 131 Tositumomab
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Iodine
Iodine-131 anti-B1 antibody
More general drug interventions related to this trial
Anti-Infective Agents
Anti-Infective Agents, Local
Antineoplastic Agents
Growth Substances
Immunologic Factors
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Trace Elements
Sponsors listed in this trial
University of Michigan Cancer Center
GlaxoSmithKline
Back to top of Main Content
